Press Releases 2023 Archives - Biocon Biologics

Leaving the Biocon Biologics Corporate Website

You are now leaving the Biocon Biologics Corporate website for a Biocon Biologics U.S. Corporate microsite that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon Biologics affiliate sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>

Leaving the Biocon Biologics Corporate Website

You are now leaving the Biocon Biologics Corporate website for a Biocon Biologics EU Corporate microsite that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon Biologics affiliate sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>

Leaving the Biocon Biologics site

You are now leaving the Biocon Biologics page for a Biocon Biologics affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon Biologics affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Brazil

Egypt

Europe

Hong Kong

Malaysia

Mexico

Morocco

Philippines

Saudi Arabia

South Africa

Taiwan

Thailand

Tunisia

Turkey

UAE

USA

Vietnam

Global HQ

Press Releases 2023

Biocon Biologics Partners with Sandoz for the Distribution of “Adalimumab BS Subcutaneous Injection [FKB]” in Japan

Biocon Biologics Concludes Integration of Acquired Biosimilars Business in ~120 countries

Biocon Biologics Recognized as an Asia IP Elite for 2023, IPR Team adjudged as the Team of the Year

Biocon Biologics Successfully Completes Integration of Viatris’ Biosimilar Business in 31 Countries in Europe

Biocon Q2FY24 Revenue at Rs 3,620 Cr, Up 52%; Biosimilars Up 97%; Research Services Up 18% EBITDA at Rs 900 Cr, Up 68%; Core EBITDA at Rs 1,100 Cr, Up 35% Net Profit at Rs 126 Cr, Up 168%

EdelGive and Hurun India recognizes Kiran Mazumdar-Shaw as the Second most generous women philanthropist in India

Biocon Biologics Announces Divestment of Two Non-Core Branded Formulations – India Business Units

Biocon Ranked No. 8 Among Science Magazine’s Best Employers in Global Biotech and Pharma Sector

Kedar Upadhye Appointed as New CFO of Biocon Biologics Current CFO MB Chinappa to take on a Strategic Finance role at Biocon Group

Biocon Board Appoints Peter Bains as Group CEO

Agree >>

Agree >>

Agree >>